References
Ma L, Delforge M, Van Duppen V, Verhowef G, Emanuel B, Boogaerts M et al. Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. Leukemia 2004; 18: 1451–1456.
Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Briere F, de Lamballeri X et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 2001; 98: 3750–3756.
Robinson SP, English N, Jaju R, Kearney L, Knight SC, Reid CDL . The in-vitro generation of dendritic cells from blast cells in acute leukaemia. Br J Haematol 1998; 103: 763–771.
Panoskaltsis N, Belanger TJ, Liesveld JL, Abboud CN . Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture. Leuk Res 2002; 26: 191–201.
Harrison BD, Adams JA, Brigs M, Brereton ML, Liu Yin JA . Stimulation of autologous proliferative and cytotoxic T-cell responses by ‘leukemic dendritic cells’ derived from blast cells in acute myeloid leukemia. Blood 2001; 97: 2764–2771.
Panoskaltsis N, Reid CDL, Knight SC . Immune modulation with dendritic cells. Transfus Med 2004; 14: 81–96.
Robinson SP, Patterson S, English N, Davies D, Knight SC, Reid CDL . Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 1999; 29: 2769–2778.
Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98: 906–912.
Knight SC, Burke F, Bedford PA . Dendritic cells, antigen distribution and the initiation of primary immune responses to self and non-self antigens. Cancer Biol 2002; 12: 301–308.
Hersh EM, Whitecar JP, McCredie KB, Bodey GP, Freireich EJ . Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med 1971; 285: 1211–1216.
Reid CDL . Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001; 112: 874–887.
Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut J et al. Human acute myeloid leukemia CD34+/CD38− progenitor cells have decreased sensitivity to chemotherapy and fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000; 60: 4403–4411.
Buggins AGS, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NSB et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-κB, c-Myc, and pRb pathways. J Immunol 2002; 167: 6021–6030.
Panoskaltsis N, Reid CDL, Knight SC . Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukemia (AML). Leukemia 2003; 17: 716–725.
Catovsky D, Lauria F, Matutes E, Foa R, Mantovani V, Tura S et al. Increase in Tγ lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1981; 47: 539–544.
Dowding C, Th’ng KH, Goldman JM, Galton DAG . Increased T-lymphocyte numbers in chronic granulocytic leukemia before treatment. Exp Hematol 1984; 12: 811–815.
Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132–2137.
Buggins AGS, Hirst WJR, Pagliuca A, Mufti GJ . Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol 1998; 100: 784–792.
Trimble LA, Kam LW, Friedman RS, Xu Z, Lieberman J . CD3ζ and CD28 down-modulation on CD8 T cells during viral infection. Blood 2000; 96: 1021–1029.
Krishnan S, Warke VG, Nambiar MP, Wong HK, Tsokos GC, Farber DL . Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3ζ expression. Blood 2001; 97: 3851–3859.
Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ . Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 3639–3645.
Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018–1023.
Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003; 111: 639–647.
Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272–3279.
Stavely-O’Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178–1183.
Takasugi M, Ramseyer A, Takasugi J . Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res 1977; 37: 413–418.
Mintz PJ, Kim J, Do K-A, Wang X, Zinner RG, Cristofanilli M et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003; 21: 57–63.
Valmori D, Dutoit V, Lienard D, Lejeune F, Speiser D, Rimoldi D et al. Tetramer-guided analysis of TCR β-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol 2000; 165: 533–538.
Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759.
Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283–8288.
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV . The presence of typical and atypical BCR–ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367.
Liu Y, Hernandez AM, Shibata D, Cortopassi GA . BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994; 91: 8910–8914.
Basecke J, Cepek L, Mannhalter C, Krauter J, Hildenhagen S, Brittinger G et al. Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia. Blood 2002; 100: 2267–2268.
Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M . Protracted and variable latency of acute lymphoblastic leukemia after TEL–AML1 gene fusion in utero. Blood 1999; 94: 1057–1062.
Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002; 99: 3801–3805.
Ford A, Bennett CA, Price CM, Bruin MCA, Van Bering ER, Greaves M . Fetal origins of the TEL–AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA 1998; 95: 4584–4588.
Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542.
Mohty M, Olive D, Gaugler B . Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts. Leukemia 2002; 16: 2197–2204.
Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001; 98: 11592–11597.
Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD . Dietary bioflavonoids induce cleavage in the Mll gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 2000; 97: 4790–4795.
Giles FJ, Keating A, Goldstone AH, Avivi I, Willman Ch, Kantarjian HM . Acute myeloid leukemia. In: Broudy VC, Abkowitz JL, Vose JM (eds). Hematology 2002. Washington, DC: The American Society of Hematology, 2002, pp 73–110.
Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM . Expression profiling of CD34+ hematopoietic stem progenitor ells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA 2002; 99: 14925–14930.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Panoskaltsis, N. Dendritic cells in MDS and AML – cause, effect or solution to the immune pathogenesis of disease?. Leukemia 19, 354–357 (2005). https://doi.org/10.1038/sj.leu.2403634
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403634
- Springer Nature Limited